Christopher Bell
Acute Care · Tupelo, MSNPI 1225190382
Payments from drug & device makers
Across 878 payments — averaging $396.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$132K
- AstraZeneca$91K
- E.r. Squibb & Sons, L.L.C.$37K
- Novo Nordisk$26K
- Scpharmaceuticals Inc.$21K
- Bridgebio Pharma, Inc.$12K
- plus $30K from 24 others
What the payments were for
- Consulting fees$40,50212%
- Speaking & faculty fees$227,01265%
- Travel & lodging$61,21518%
- Food & beverage$18,9845%
- Education$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 290 | $131,885 |
| AstraZeneca | 138 | $90,508 |
| E.r. Squibb & Sons, L.L.C. | 81 | $37,082 |
| Novo Nordisk | 25 | $25,974 |
| Scpharmaceuticals Inc. | 26 | $20,510 |
| Bridgebio Pharma, Inc. | 38 | $12,294 |
| Akcea Therapeutics, Inc. | 16 | $6,476 |
| Vifor Pharma, Inc. | 7 | $5,218 |
| Cvrx, Inc. | 8 | $4,307 |
| Impulse Dynamics (USA) Inc. | 12 | $4,163 |
| Boston Scientific | 95 | $2,292 |
| Medtronic | 16 | $1,994 |
| Boehringer Ingelheim | 13 | $1,300 |
| Novartis | 22 | $998 |
| Abbott | 13 | $961 |
| Pfizer | 31 | $401 |
| Biotronik Inc. | 5 | $369 |
| Abiomed | 9 | $350 |
| Merck | 15 | $271 |
| Nuwellis, Inc. | 1 | $93 |
| Johnson & Johnson | 2 | $63 |
| Lexicon Pharmaceuticals, Inc. | 1 | $55 |
| Amgen | 4 | $55 |
| Daiichi Sankyo Inc. | 2 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Daxor Corporation | 1 | $41 |
| Bayer | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMVUTTRA$106,926
- WAINUA$77,075
- CAMZYOS$31,210
- FUROSCIX$20,361
- ONPATTRO$18,612
- Attruby$11,686
- FARXIGA$10,426
- OPTIMIZER$7,762
- Ozempic$7,166
- TEGSEDI$5,443
- Veltassa$5,104
- Barostim Neo System$4,124
- SYMPLICITY G3$1,314
- LEQVIO$688
- FreeStyle Libre Pro$500
- CARDIOMEMS$148
- LUX-Dx Insertable Cardiac Monitor$123
- MitraClip System$106
- JARDIANCE$101
- WATCHMAN FLX$101
How this compares
$347,826 in reported general payments places this provider in the 95th percentile of 223 acute care providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 77 | $1,853,928 |
| CamzyosMavacamten | 101 | $808,517 |
| EliquisApixaban | 608 | $528,145 |
| FarxigaDapagliflozin Propanediol | 299 | $286,425 |
| VyndaqelTafamidis Meglumine | 11 | $245,655 |
| JardianceEmpagliflozin | 279 | $225,922 |
| XareltoRivaroxaban | 190 | $191,788 |
| Repatha SureclickEvolocumab | 171 | $167,441 |
| EntrestoSacubitril/Valsartan | 130 | $147,173 |
| Praluent PenAlirocumab | 58 | $47,520 |
| OzempicSemaglutide | 34 | $35,033 |
| BrilintaTicagrelor | 20 | $18,950 |
| Ranolazine ErRanolazine | 220 | $18,369 |
| Ezetimibe | 707 | $12,902 |
| Carvedilol | 1,698 | $10,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis, Vyndaqel | $401 | $2,627,728696 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $37,082 | $808,517101 claims |
| AstraZenecaFarxiga, Brilinta | $90,508 | $305,375319 claims |
| Boehringer IngelheimJardiance, Pradaxa | $1,300 | $229,750295 claims |
| Johnson & JohnsonXarelto | $63 | $191,788190 claims |
| NovartisEntresto | $998 | $147,173130 claims |
| Novo NordiskOzempic | $25,974 | $35,03334 claims |
| MerckVerquvo | $271 | $9,93411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 acute care providers in Mississippi.
Other acute care in Tupelo
- Megan WilliamsTupelo$11K
- Starla HortonTupelo$3K
- Robin JacksonTupelo$3K
- Cynthia SmithTupelo$3K
- Kathleen ArnoldOcean Springs$217K
- Gavin GistOxford$42K
- Jamie DamicoOcean Springs$17K
- Dylan BoydHattiesburg$15K
- Melinda ClarkStarkville$14K
- Michelle TaylorGulfport$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.